174 related articles for article (PubMed ID: 25172457)
1. Ruxolitinib-associated tuberculosis: a case of successful ruxolitinib rechallenge.
Palandri F; Polverelli N; Catani L; Vianelli N
Ann Hematol; 2015 Mar; 94(3):519-20. PubMed ID: 25172457
[No Abstract] [Full Text] [Related]
2. A phase I study of panobinostat and ruxolitinib in patients with primary myelofibrosis (PMF) and post--polycythemia vera/essential thrombocythemia myelofibrosis (post--PV/ET MF).
Mascarenhas J; Marcellino BK; Lu M; Kremyanskaya M; Fabris F; Sandy L; Mehrotra M; Houldsworth J; Najfeld V; El Jamal S; Petersen B; Moshier E; Hoffman R
Leuk Res; 2020 Jan; 88():106272. PubMed ID: 31778911
[TBL] [Abstract][Full Text] [Related]
3. [Hematologic Malignancies/Pediatric Malignancies. I. Ruxolitinib Therapy for Myelofibrosis and Polycythemia Vera].
Komatsu N
Gan To Kagaku Ryoho; 2016 May; 43(5):530-4. PubMed ID: 27344680
[No Abstract] [Full Text] [Related]
4. Tuberculosis reactivation related with ruxolitinib in a patient with primary myelofibrosis.
Pepeler MS; Özkurt ZN; Güzel ÖT; Akyürek N
J Infect Dev Ctries; 2018 Oct; 12(10):926-928. PubMed ID: 32004164
[TBL] [Abstract][Full Text] [Related]
5. Tuberculosis and atypical mycobacterial infections in ruxolitinib-treated patients with primary or secondary myelofibrosis or polycythemia vera.
Lescuyer S; Ledoux MP; Gravier S; Natarajan-Amé S; Duval C; Maloisel F; Mauvieux L; Toussaint E; Fornecker LM; Herbrecht R
Int J Infect Dis; 2019 Mar; 80():134-136. PubMed ID: 30639623
[TBL] [Abstract][Full Text] [Related]
6. Overcoming treatment challenges in myelofibrosis and polycythemia vera: the role of ruxolitinib.
Bryan JC; Verstovsek S
Cancer Chemother Pharmacol; 2016 Jun; 77(6):1125-42. PubMed ID: 27017614
[TBL] [Abstract][Full Text] [Related]
7. Restoration of response to ruxolitinib upon brief withdrawal in two patients with myelofibrosis.
Gisslinger H; Schalling M; Gisslinger B; Skrabs C; Müllauer L; Kralovics R
Am J Hematol; 2014 Mar; 89(3):344-6. PubMed ID: 24273107
[No Abstract] [Full Text] [Related]
8. The impact of ruxolitinib on thrombosis in patients with polycythemia vera and myelofibrosis: a meta-analysis.
Samuelson BT; Vesely SK; Chai-Adisaksopha C; Scott BL; Crowther M; Garcia D
Blood Coagul Fibrinolysis; 2016 Sep; 27(6):648-52. PubMed ID: 26569516
[TBL] [Abstract][Full Text] [Related]
9. Tumor Lysis Syndrome after the Administration of Ruxolitinib in a Patient with Post-polycythemia Vera Myelofibrosis.
Koshiishi M; Sueki Y; Kawashima I; Nakajima K; Mitsumori T; Kirito K
Intern Med; 2017 Sep; 56(17):2335-2338. PubMed ID: 28794380
[TBL] [Abstract][Full Text] [Related]
10. [Fatal tuberculosis during treatment with ruxolitinib].
Keizer S; Gerritsen R; Jauw Y; Janssen J; Koopman B; Bresser P
Ned Tijdschr Geneeskd; 2015; 159():A8650. PubMed ID: 25990328
[TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of combination therapy of interferon-α2 and ruxolitinib in polycythemia vera and myelofibrosis.
Mikkelsen SU; Kjaer L; Bjørn ME; Knudsen TA; Sørensen AL; Andersen CBL; Bjerrum OW; Brochmann N; Fassi DE; Kruse TA; Larsen TS; Mourits-Andersen HT; Nielsen CH; Pallisgaard N; Thomassen M; Skov V; Hasselbalch HC
Cancer Med; 2018 Aug; 7(8):3571-3581. PubMed ID: 29932310
[TBL] [Abstract][Full Text] [Related]
12. A journey through infectious risk associated with ruxolitinib.
Sant'Antonio E; Bonifacio M; Breccia M; Rumi E
Br J Haematol; 2019 Nov; 187(3):286-295. PubMed ID: 31468506
[TBL] [Abstract][Full Text] [Related]
13. Combination therapy with interferon and ruxolitinib for polycythemia vera and myelofibrosis: are two drugs better than one?
Silver RT
Haematologica; 2020 Sep; 105(9):2190-2191. PubMed ID: 33054041
[No Abstract] [Full Text] [Related]
14. Ruxolitinib Enhances Platelet Production in Patients With Thrombocytopenic Myelofibrosis.
Grunwald MR; Spivak JL
J Clin Oncol; 2016 Feb; 34(5):e38-40. PubMed ID: 24958831
[No Abstract] [Full Text] [Related]
15. Efficacy and safety of JAK inhibitor INC424 in patients with primary and post-polycythemia vera or post-essential thrombocythemia myelofibrosis in the Chinese population.
Du X; Zhou D
Front Med; 2016 Dec; 10(4):437-443. PubMed ID: 27858230
[TBL] [Abstract][Full Text] [Related]
16. Ruxolitinib rechallenge in combination with hydroxyurea is effective in reverting cachexia and reducing blood transfusion demand and splenomegaly symptoms in a patient with primary myelofibrosis.
Cerchione C; Peluso I; Nappi D; Pareto AE; Picardi M; Martinelli V; Pane F
Ann Hematol; 2017 Apr; 96(4):697-699. PubMed ID: 28197723
[No Abstract] [Full Text] [Related]
17. Isolated Nodal TBC Reactivation in a Patient with Post-Thrombocythemia Myelofibrosis Treated with Ruxolitinib: Case Report and Review of the Literature.
Santoro M; Rotolo C; Accurso V; Morreale I; Mancuso S; Siragusa S
Chemotherapy; 2021; 66(3):87-91. PubMed ID: 33784668
[TBL] [Abstract][Full Text] [Related]
18. Population pharmacokinetic analysis of orally-administered ruxolitinib (INCB018424 Phosphate) in patients with primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF) or post-essential thrombocythemia myelofibrosis (PET MF).
Chen X; Williams WV; Sandor V; Yeleswaram S
J Clin Pharmacol; 2013 Jul; 53(7):721-30. PubMed ID: 23677817
[TBL] [Abstract][Full Text] [Related]
19. Serious adverse events during ruxolitinib treatment discontinuation in patients with myelofibrosis.
Tefferi A; Pardanani A
Mayo Clin Proc; 2011 Dec; 86(12):1188-91. PubMed ID: 22034658
[TBL] [Abstract][Full Text] [Related]
20. Imatinib and ruxolitinib association: first experience in two patients.
Iurlo A; Gianelli U; Rapezzi D; Cattaneo D; Fermo E; Binda F; Santambrogio E; Bucelli C; Cortelezzi A
Haematologica; 2014 Jun; 99(6):e76-7. PubMed ID: 24633869
[No Abstract] [Full Text] [Related]
[Next] [New Search]